Preface content

  • Early animal studies by Pirbright and Oxford yield promising results

    for new potential COVID-19 vaccine

  • Pirbright to study the threats of new SARS-CoV-2 variants as part of a new consortium

  • Pirbright study shows how SARS-CoV-2 could have adapted from bats to humans

    and which other animals it could infect

  • Mosquito gene discovery by Pirbright scientists could be harnessed to curb

    global malaria spread

  • Latest Pirbright collaboration uncovers genetic markers that could guide

    avian influenza surveillance

  • Visit our Coronavirus Hub

  • Pirbright African swine fever vaccine protects 100% of pigs

    from developing severe disease

  • Current vacancies at Pirbright

  • Director's vision

Innovation and collaboration

Trim content

® The Pirbright Institute 2021 | A company limited by guarantee, registered in England no. 559784. The Institute is also a registered charity.